Development of a Manufacturing Process for Sibenadet Hydrochloride, the Active Ingredient of Viozan-Reference-Cited by-同舟云学术

Development of a Manufacturing Process for Sibenadet Hydrochloride, the Active Ingredient of Viozan

Published:2004-06-16 Issue:4 Volume:8 Page:628-642
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Giles Melvyn E.¹,Thomson Colin¹,Eyley Stephen C.¹,Cole Andrea J.¹,Goodwin Christopher J.¹,Hurved Paul A.¹,Morlin Andrew J. G.¹,Tornos James¹,Atkinson Stéphanie¹,Just Cecelia¹,Dean Janet C.¹,Singleton John T.¹,Longton Andrew J.¹,Woodland Ian¹,Teasdale Andrew¹,Gregertsen Björn¹,Else Howard¹,Athwal Mandip S.¹,Tatterton Stephen¹,Knott Jason M.¹,Thompson Nicola¹,Smith Stephen J.¹

Affiliation:

1. AstraZeneca R & D Charnwood, Process R & D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/op049953y

Reference25 articles.

1. Long-term use of Viozan™ (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study

2. Dual D2-Receptor and β2-Adrenoceptor Agonists for the Treatment of Airway Diseases. 1. Discovery and Biological Evaluation of Some 7-(2-Aminoethyl)- 4-hydroxybenzothiazol-2(3H)-one Analogues

3. Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent: benzothiazol-2-one 7-ethylamines